Sarepta Therapeutics falls after FDA probes death of Elevidys patient

Shares of drugmaker Sarepta Therapeutics SRPT.O fall 7% to $11.10 in extended trading

The US FDA says it is investigating the death of an 8-year-old boy who received Elevidys, a gene therapy for Duchenne muscular dystrophy

Roche ROG.S, which partners with Sarepta outside the U.S., said the boy was treated with Elevidys and was not a participant in a clinical trial

"The reporting physician has assessed the death as unrelated to treatment with Elevidys," says Roche

This is the third reported death of a patient who received Elevidys, and the fourth death this year tied to Sarepta's gene therapies

The boy died on June 7 - FDA

Last week, the agency asked Sarepta to voluntarily halt shipments of Elevidys

Stock down 90% YTD